457 related articles for article (PubMed ID: 32209637)
21. Interleukin 10 decreases MICA expression on melanoma cell surface.
Serrano AE; Menares-Castillo E; Garrido-Tapia M; Ribeiro CH; Hernández CJ; Mendoza-Naranjo A; Gatica-Andrades M; Valenzuela-Diaz R; Zúñiga R; López MN; Salazar-Onfray F; Aguillón JC; Molina MC
Immunol Cell Biol; 2011 Mar; 89(3):447-57. PubMed ID: 20714339
[TBL] [Abstract][Full Text] [Related]
22. A vaccine targeting resistant tumours by dual T cell plus NK cell attack.
Badrinath S; Dellacherie MO; Li A; Zheng S; Zhang X; Sobral M; Pyrdol JW; Smith KL; Lu Y; Haag S; Ijaz H; Connor-Stroud F; Kaisho T; Dranoff G; Yuan GC; Mooney DJ; Wucherpfennig KW
Nature; 2022 Jun; 606(7916):992-998. PubMed ID: 35614223
[TBL] [Abstract][Full Text] [Related]
23. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
25. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A.
Busche A; Goldmann T; Naumann U; Steinle A; Brandau S
Hum Gene Ther; 2006 Feb; 17(2):135-46. PubMed ID: 16454647
[TBL] [Abstract][Full Text] [Related]
30. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.
Xie W; Liu F; Wang Y; Ren X; Wang T; Chen Z; Tang M; Sun F; Li Z; Wang M; Zhang J
Oncotarget; 2016 Mar; 7(13):16445-61. PubMed ID: 26909862
[TBL] [Abstract][Full Text] [Related]
31. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
32. STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells.
Garrido-Tapia M; Hernández CJ; Ascui G; Kramm K; Morales M; Ga Rate V; Zúñiga R; Bustamante M; Aguillón JC; Catala N D; Ribeiro CH; Molina MAC
Immunobiology; 2017 Nov; 222(11):1043-1051. PubMed ID: 28578917
[TBL] [Abstract][Full Text] [Related]
33. NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B.
Lee HH; Kim D; Jung J; Kang H; Cho H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502191
[TBL] [Abstract][Full Text] [Related]
34. MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells.
Morimoto Y; Yamashita N; Daimon T; Hirose H; Yamano S; Haratake N; Ishikawa S; Bhattacharya A; Fushimi A; Ahmad R; Takahashi H; Dashevsky O; Mitsiades C; Kufe D
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754452
[TBL] [Abstract][Full Text] [Related]
35. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
36. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
[TBL] [Abstract][Full Text] [Related]
37. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
38. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
40. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells.
Wang B; Wang Q; Wang Z; Jiang J; Yu SC; Ping YF; Yang J; Xu SL; Ye XZ; Xu C; Yang L; Qian C; Wang JM; Cui YH; Zhang X; Bian XW
Cancer Res; 2014 Oct; 74(20):5746-57. PubMed ID: 25164008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
